Dr. Andre P. Fay, M.D. discusses Whole-Exome Sequencing Predicting Two Extreme Phenotypes of Response to VEGF-targeted Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mRCC) at the Kidney Cancer meeting in Chicago
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content